Immutep announces publication of TACTI-002 abstract at ESMO’s European Lung Cancer Congress 2022
Immutep announces publication of TACTI-002 abstract at ESMO’s European Lung Cancer Congress 2022
- New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in second line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients
- Combination continues to be safe and well tolerated, and shows encouraging signs of antitumour activity in this difficult to treat patient population with limited treatment options
- Overall Response Rate (ORR) of 6 percent (2/36) and Disease Control Rate (DCR) of 36 percent (13/36) in the intent to treat population; both partial responses are confirmed and durable
- Important additional data on safety and efficacy including 6 months Overall Survival (OS), Tumour Growth Kinetics, and details of the confirmed partial responses will be presented in the poster at ELCC
Sydney, Australia, March 24, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that new interim data from 2nd line NSCLC patients (Part B) of its phase II TACTI-002 trial has been published in an abstract today in advance of ESMO’s European Lung Cancer Congress (ELCC) 2022. ELCC 2022 will now be taking place in a virtual only format from 30 March 2022 to 2 April 2022.
Title: Results of phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
Abstract: Available at https://tinyurl.com/ycx5hwhr
The related poster presentation with new and updated data that are not part of the abstract will now be released by ELCC on 29 March 2022 at 12:00 noon, CEST and will subsequently be made available on Immutep’s website at www.immutep.com.
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506